Lumos Pharma completed its merger with Double Point Ventures, acquiring a majority of shares through a tender offer.Quiver AI SummaryLumos Pharma, Inc. and Double Point Ventures LLC announced the completion...
Lumos Pharma presented positive Phase 2 trial data for oral LUM-201, showing sustained growth in pediatric patients with hormone deficiency.Quiver AI SummaryLumos Pharma, Inc. has presented new analyses...
-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials...
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for...